Classic hyperacute rejection is dependent on the activation of terminal components complement. Recently, xenoantibodies with limited abilities to activate classical pathway complement in vitro have been implicated acute vascular xenografts. It unclear how these Abs affect their pathogenic activities vivo. In this study, we demonstrate ability an anti-Gal-α1,3Gal (Gal) IgG1, modest complement-ac...